BerGenBio ASA
7BG0
Company Profile
Business description
BerGenBio ASA is a clinical-stage biopharmaceutical company developing drugs for aggressive diseases, including drug resistant and metastatic cancers and respiratory disease. Its product, bemcentinib (BGB324), is a selective, potent, oral small molecule AXL inhibitor that has been tested in a various indications including NSCLC, AML and severe respiratory infections.
Contact
Nygardsgaten 114
Bergen5008
NORT: +47 55961159
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,826.70 | 48.80 | 0.56% |
| CAC 40 | 7,902.25 | 0.00 | 0.00% |
| DAX 40 | 24,456.81 | 92.75 | -0.38% |
| Dow JONES (US) | 44,735.80 | 277.50 | 0.62% |
| FTSE 100 | 8,975.66 | 108.64 | 1.23% |
| HKSE | 24,028.37 | 136.05 | 0.57% |
| NASDAQ | 20,622.16 | 10.82 | 0.05% |
| Nikkei 225 | 39,646.36 | 174.92 | -0.44% |
| NZX 50 Index | 12,760.20 | 8.41 | -0.07% |
| S&P 500 | 6,283.33 | 20.07 | 0.32% |
| S&P/ASX 200 | 8,589.20 | 50.60 | 0.59% |
| SSE Composite Index | 3,509.68 | 16.63 | 0.48% |